Tha Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer
Protocol: Alliance – A022104 SCHEMA A022104 Please Note: Below is a partial list of eligibility, please contact Genesys Hurley Cancer Institute, Research Department at (810) 762-8181, (810) 762-8079 or (810) 762-8038 to discuss full list of eligibility requirements. Thank you! Eligibility: Clinical stage II or III rectal adenocarcinoma defined as T4N0, or any T with […]
Randomized Trial of Consolidation Targeted Adjuvant Therapy with Encorafenib and Cetuximab Versus Usual Care for Patients with stage II/III BRAF V600E Colon Cancer
Protocol: Alliance – A022004 SCHEMA A022004 Please Note: Below is a partial list of eligibility, please contact Genesys Hurley Cancer Institute, Research Department at (810) 762-8181, (810) 762-8079 or (810) 762-8038 to discuss full list of eligibility requirements. Thank you! Eligibility: Histologically-proven stage III (any T [Tx, T1, T2, T3, or T4], N1-2M0; includes N1C) […]
A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation and Surgery
Protocol: Alliance – A022101 SCHEMA A022101 Please Note: Below is a partial list of eligibility, please contact Genesys Hurley Cancer Institute, Research Department at (810) 762-8181, (810) 762-8079 or (810) 762-8068 to discuss full eligibility requirements. Thank you! Eligibility: Histologically-confirmed metastatic colorectal adenocarcinoma No known microsatellite instable tumor No known brain metastases No known peritoneal […]
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Protocol: NRG-GI008 SCHEMA NRG-GI008 Please Note: Below is partial eligibility, for full eligibility requirements, please contact Genesys Hurley Cancer Institute, Research Department at (810)762-8181, (810)762-8079 and/or (810)762-8038. Thank you! Eligibility: The patient must be ≥ 18 years old. The patient must have an ECOG performance status of 0 or 1. Patients must have histologically/pathologically confirmed Stage […]
Randomized Phase II Trial of Encorafenib and Cetuximab with or without Nivolumab for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Protocol: SWOG – S2107 SCHEMA S2107 Please Note: Below is partial eligibility, for full eligibility requirements, please contact Genesys Hurley Cancer Institute at (810)762-8181, (810)762-8079 and/or (810)762-8038, Thank you! Eligibility: Participants must have a histologically or cytologically confirmed diagnosis of adenocarcinoma of the colon or rectum. Participants must have measurable disease. Participants must have documented […]
A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizum in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Protocol – NRG – GI004 SCHEMA NRG-GI004-S1610 Please Note: Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810)762-8038. Thank you! Eligibility: At least 18 years of age. ECOG Performance Status 0-2. Diagnosis of metastatic adenocarcinoma of colon or rectum without previous chemotherapy or any […]
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma.
Protocol: SWOG – S1922 SCHEMA S1922 Please Note: Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810)762-8038. Thank you! Eligibility: Patients must have histologically or cytologically confirmed small bowel adenocarcinoma. Ampullary adenocarcinomas are not eligible. Patients must have metastatic disease or locally advanced unresectable […]